Alexandra Balcom Nuvalent, Inc. (NUVL) insider trading activity

Alexandra Balcom is Chief Financial Officer of Nuvalent, Inc.. Currently has a direct ownership of 61,734 shares of NUVL, which is worth approximately $6.05 Million. The most recent transaction as insider was on Sep 30, 2024, when has been sold 10,000 shares (Class A Common Stock) at a price of $100.5 per share, resulting in proceeds of $1,005,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 61.7K

0% 3M change

85.39% 12M change

Total Value Held $6.05 Million

Alexandra Balcom Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2024	SELL Open market or private sale	$1,005,000 $100.5 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Sep 30 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Aug 30 2024	SELL Open market or private sale	$847,900 $84.79 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Aug 30 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Jul 31 2024	SELL Open market or private sale	$792,400 $79.24 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Jul 31 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Jun 28 2024	SELL Open market or private sale	$760,200 $76.02 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Jun 28 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Jan 05 2024	BUY Grant, award, or other acquisition	-	33,300 Added 50.0%	33,300 Class A Common Stock
Dec 18 2023	SELL Open market or private sale	$2,274,600 $75.82 p/Share	30,000 Reduced 100.0%	0 Class A Common Stock
Dec 18 2023	BUY Exercise of conversion of derivative security	$32,400 $1.08 p/Share	30,000 Added 50.0%	30,000 Class A Common Stock
Jul 31 2023	SELL Open market or private sale	$1,226,250 $49.05 p/Share	25,000 Reduced 100.0%	0 Class A Common Stock
Jul 31 2023	BUY Exercise of conversion of derivative security	$27,000 $1.08 p/Share	25,000 Added 50.0%	25,000 Class A Common Stock

Also insider at

GLYC

GLYCOMIMETICS INC Healthcare

Director